Zafgen Stock Price, News & Analysis (NASDAQ:ZFGN)

$3.77 0.07 (1.89 %)
(As of 11/17/2017 02:20 PM ET)
Previous Close$3.77
Today's Range$3.80 - $3.68
52-Week Range$3.11 - $5.46
Volume43,053 shs
Average Volume203,787 shs
Market Capitalization$101.71 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.34

About Zafgen (NASDAQ:ZFGN)

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:ZFGN
  • CUSIP: N/A
  • Web: www.zafgen.com
Debt:
  • Current Ratio: 13.61%
  • Quick Ratio: 13.61%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $3.25 per share
  • Price / Book: 1.16
Profitability:
  • Trailing EPS: ($1.80)
  • Net Income: ($57,870,000.00)
  • Return on Equity: -46.88%
  • Return on Assets: -43.31%
Misc:
  • Employees: 32
  • Outstanding Shares: 27,490,000
 

Frequently Asked Questions for Zafgen (NASDAQ:ZFGN)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen, Inc. (NASDAQ:ZFGN) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.12. View Zafgen's Earnings History.

Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?

2 equities research analysts have issued 1 year price objectives for Zafgen's stock. Their predictions range from $9.00 to $9.00. On average, they expect Zafgen's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Zafgen.

Who are some of Zafgen's key competitors?

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:

  • Peter Barrett Ph.D., Independent Chairman of the Board (Age 64)
  • Thomas E. Hughes Ph.D., President, Chief Scientific Officer, Director (Age 57)
  • Jeffrey S. Hatfield, Chief Executive Officer, Director
  • Patricia L. Allen CPA, Chief Financial Officer (Age 54)
  • Dennis D. Kim M.D., Chief Medical Officer (Age 46)
  • Bruce L. Booth Ph.D., Director (Age 42)
  • Thomas O. Daniel M.D., Director (Age 63)
  • Geoffrey McDonough M.D., Director (Age 47)
  • Robert J. Perez, Director (Age 52)
  • Frances K. Heller J.D., Independent Director (Age 49)

Who owns Zafgen stock?

Zafgen's stock is owned by many different of institutional and retail investors. Top institutional investors include Mangrove Partners (2.04%), OxFORD Asset Management LLP (0.62%) and Candriam Luxembourg S.C.A. (0.47%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.

Who sold Zafgen stock? Who is selling Zafgen stock?

Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Zafgen.

Who bought Zafgen stock? Who is buying Zafgen stock?

Zafgen's stock was bought by a variety of institutional investors in the last quarter, including Mangrove Partners and OxFORD Asset Management LLP. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.

How do I buy Zafgen stock?

Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of Zafgen stock can currently be purchased for approximately $3.77.

How big of a company is Zafgen?

Zafgen has a market capitalization of $101.71 million. The biopharmaceutical company earns ($57,870,000.00) in net income (profit) each year or ($1.80) on an earnings per share basis. Zafgen employs 32 workers across the globe.

How can I contact Zafgen?

Zafgen's mailing address is 175 Portland St Fl 4, BOSTON, MA 02114-1713, United States. The biopharmaceutical company can be reached via phone at +1-617-6224003 or via email at [email protected]


MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Zafgen (NASDAQ:ZFGN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.00 (138.73% upside)

Consensus Price Target History for Zafgen (NASDAQ:ZFGN)

Price Target History for Zafgen (NASDAQ:ZFGN)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$9.00HighView Rating Details
3/10/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/7/2017FBR & CoReiterated RatingMarketperformLowView Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00N/AView Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00N/AView Rating Details
4/5/2016Royal Bank Of CanadaReiterated RatingOutperform$19.00N/AView Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingHold$7.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Zafgen (NASDAQ:ZFGN)

Earnings by Quarter for Zafgen (NASDAQ:ZFGN)

Earnings History by Quarter for Zafgen (NASDAQ ZFGN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.58)($0.46)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.49)ViewListenView Earnings Details
5/9/2017Q1 2017($0.43)($0.48)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.50)($0.38)ViewListenView Earnings Details
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zafgen (NASDAQ:ZFGN)
2017 EPS Consensus Estimate: ($2.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.41)($0.45)
Q2 20172($0.58)($0.53)($0.56)
Q3 20172($0.64)($0.54)($0.59)
Q4 20172($0.70)($0.59)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zafgen (NASDAQ ZFGN)

Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 48.40%
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)

Insider Trades by Quarter for Zafgen (NASDAQ ZFGN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Frances K HellerDirectorBuy10,000$3.90$39,000.00View SEC Filing  
7/11/2017Dennis D KimInsiderBuy10,000$3.39$33,900.00View SEC Filing  
5/11/2017Dennis D. KimInsiderBuy10,000$4.40$44,000.00View SEC Filing  
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.00View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.00View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.00View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.00View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zafgen (NASDAQ:ZFGN)

Latest Headlines for Zafgen (NASDAQ ZFGN)

Source:
DateHeadline
Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"
www.americanbankingnews.com - November 11 at 10:22 AM
Leerink Swann Comments on Zafgen, Inc.s FY2017 Earnings (ZFGN)Leerink Swann Comments on Zafgen, Inc.'s FY2017 Earnings (ZFGN)
www.americanbankingnews.com - November 10 at 12:26 PM
Zafgen, Inc. (ZFGN) Announces Quarterly  Earnings Results, Beats Expectations By $0.12 EPSZafgen, Inc. (ZFGN) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Zafgen Reports Third Quarter 2017 Financial ResultsZafgen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:28 PM
Zafgen reports 3Q lossZafgen reports 3Q loss
finance.yahoo.com - November 7 at 9:28 PM
Head to Head Contrast: Zafgen (ZFGN) & Its RivalsHead to Head Contrast: Zafgen (ZFGN) & Its Rivals
www.americanbankingnews.com - November 1 at 3:12 AM
Zafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on TuesdayZafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
Financial Contrast: Zafgen (ZFGN) versus Its CompetitorsFinancial Contrast: Zafgen (ZFGN) versus Its Competitors
www.americanbankingnews.com - October 30 at 11:40 AM
Zafgen Inc (ZFGN) Receives Average Rating of "Hold" from BrokeragesZafgen Inc (ZFGN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 5:48 PM
Zafgen, Inc. (ZFGN) Director Acquires $39,000.00 in StockZafgen, Inc. (ZFGN) Director Acquires $39,000.00 in Stock
www.americanbankingnews.com - October 17 at 8:18 PM
Zafgen, Inc. (ZFGN) Rating Lowered to Hold at Zacks Investment ResearchZafgen, Inc. (ZFGN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:52 PM
Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - October 13 at 10:35 AM
Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - October 13 at 10:35 AM
Zafgen (ZFGN) Announces Jeffrey Hatfield as New CEO; Thomas Hughes to Remain President, Assume Chief ... - StreetInsider.comZafgen (ZFGN) Announces Jeffrey Hatfield as New CEO; Thomas Hughes to Remain President, Assume Chief ... - StreetInsider.com
www.streetinsider.com - October 10 at 8:37 AM
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific OfficerZafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
finance.yahoo.com - October 10 at 8:37 AM
When Will Zafgen Inc (ZFGN) Run Out Of Cash?When Will Zafgen Inc (ZFGN) Run Out Of Cash?
finance.yahoo.com - October 5 at 8:17 AM
Zafgen, Inc. (ZFGN) Given Consensus Recommendation of "Hold" by BrokeragesZafgen, Inc. (ZFGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 1 at 2:20 PM
-$0.54 EPS Expected for Zafgen Inc (ZFGN) This Quarter-$0.54 EPS Expected for Zafgen Inc (ZFGN) This Quarter
www.americanbankingnews.com - September 28 at 8:28 AM
Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 DiabetesZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
www.streetinsider.com - September 14 at 12:06 PM
Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.comZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.com
www.streetinsider.com - September 13 at 1:42 AM
Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 DiabetesZafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
finance.yahoo.com - September 12 at 8:41 PM
Zafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.comZafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.com
www.streetinsider.com - September 12 at 12:38 PM
Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of DiabetesZafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
finance.yahoo.com - September 12 at 12:38 PM
Zafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from AnalystsZafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 5:16 PM
Zafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by AnalystsZafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 12 at 5:02 PM
Q3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)Q3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)
www.americanbankingnews.com - August 11 at 7:48 AM
Zafgen, Inc. (ZFGN) Releases  Earnings Results, Beats Estimates By $0.03 EPSZafgen, Inc. (ZFGN) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:22 PM
Zafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Zafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 3:29 PM
Investor Network: Zafgen, Inc. to Host Earnings CallInvestor Network: Zafgen, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 9:28 AM
Zafgen Reports Second Quarter 2017 Financial ResultsZafgen Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 9:28 AM
Zafgen reports 2Q lossZafgen reports 2Q loss
finance.yahoo.com - August 9 at 9:28 AM
Zafgen to Present at the Canaccord Genuity 37th Annual Growth ConferenceZafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 9:13 AM
Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial ResultsZafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 9:03 AM
Zafgen, Inc. (ZFGN) Scheduled to Post Earnings on WednesdayZafgen, Inc. (ZFGN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:45 AM
Zafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from AnalystsZafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 5:31 PM
Zafgen, Inc. (NASDAQ:ZFGN) Short Interest UpdateZafgen, Inc. (NASDAQ:ZFGN) Short Interest Update
www.americanbankingnews.com - July 16 at 7:14 AM
BUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Teva, Tesaro - NasdaqBUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Teva, Tesaro - Nasdaq
www.nasdaq.com - July 13 at 3:33 PM
Dennis D. Kim Acquires 10,000 Shares of Zafgen, Inc. (NASDAQ:ZFGN) StockDennis D. Kim Acquires 10,000 Shares of Zafgen, Inc. (NASDAQ:ZFGN) Stock
www.americanbankingnews.com - July 12 at 8:45 PM
Zafgen to Present at the JMP Securities Life Sciences Conference - GlobeNewswire (press release)Zafgen to Present at the JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 14 at 4:30 PM
Zafgen (ZFGN) Announces New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes & Obesity - StreetInsider.comZafgen (ZFGN) Announces New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes & Obesity - StreetInsider.com
www.streetinsider.com - June 12 at 6:27 AM
Zafgen Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)Zafgen Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 8:26 PM
Zafgens Second ActZafgen's Second Act
seekingalpha.com - May 11 at 3:25 PM
Zafgen updates on obesity drug - Seeking AlphaZafgen updates on obesity drug - Seeking Alpha
seekingalpha.com - May 6 at 3:45 PM
Zafgen Gets One Last Fat Chance - Seeking AlphaZafgen Gets One Last Fat Chance - Seeking Alpha
seekingalpha.com - May 6 at 3:45 PM
Zafgen (ZFGN) Reports Positive Topline Phase 1 Data for ZGN-1061 - StreetInsider.comZafgen (ZFGN) Reports Positive Topline Phase 1 Data for ZGN-1061 - StreetInsider.com
www.streetinsider.com - May 5 at 5:40 AM
Zafgen Reports Fourth Quarter and Full Year 2016 Financial ResultsZafgen Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 11 at 11:29 AM
4:11 pm Zafgen beats by $0.12, reports no revenue4:11 pm Zafgen beats by $0.12, reports no revenue
us.rd.yahoo.com - March 11 at 11:29 AM
ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 11 at 11:29 AM
ZAFGEN, INC. Files SEC form 10-K, Annual ReportZAFGEN, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 11 at 11:29 AM
Zafgen (ZFGN) Presents At Cowen and Company 37th Annual Health Care ConferenceZafgen (ZFGN) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 6:30 AM

Social Media

Financials

Chart

Zafgen (NASDAQ ZFGN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.